Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy

Tarannum, Mubin; Romee, Rizwan; Shapiro, Roman M

doi:10.3389/fimmu.2022.859177

Cited by 28 publications

(21 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple groups have adopted and enhanced KIR-ligand mismatching protocols [183][184][185][186] (a recent extensive review is given elsewhere 187 ), which have helped pave the way toward targeted NK cell therapies for the same leukemias and other cancers. [188][189][190] Nevertheless, effect differences remain across transplant centers or treatment regimens, 191 and further refinement of matching protocols will likely be aided through refinement of the genotyping methods. 192,193 The previous findings, together with the established links between peripheral NK cell quantity and disease course, also imply that NK cells can be harnessed to treat autoimmune and other chronic diseases, as they have for malignancies.…”

Section: Kir/hla In Immune Therapymentioning

confidence: 99%

Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health

Pollock

Harrison

Norman

2022

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

Section: Kir/hla In Immune Therapymentioning

confidence: 99%

Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health

Pollock

Harrison

Norman

2022

The Journal of Allergy and Clinical Immunology: In Practice

View full text Add to dashboard Cite

“…In fact, CD33-CAR NK-92 cells do not appear to be effective against AML in the first CAR-NK92 clinical trial (NCT02944162) ( 34 ). Alternatively, iPSC-derived NK cells are a homogeneous, unlimited, and easy-to-edit option but their manufacturing is lengthy and requires specialized expertise ( 41 ).…”

Section: Manufacturing Conditions: Key Aspect For the Efficacy Of Car...mentioning

confidence: 99%

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

et al. 2022

View full text Add to dashboard Cite

Despite the impressive results of autologous CAR-T cell therapy in refractory B lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost-effective approach with no signs of severe toxicities as described for CAR-T cells. Permanently scrutinized for its efficacy, recent promising data in CAR-NK clinical trials point out the achievement of deep, high-quality responses, thus confirming its potential clinical use. Although CAR-NK cell therapy is not significantly affected by the loss or downregulation of its CAR tumor target, as in the case of CAR-T cell, a plethora of common additional tumor intrinsic or extrinsic mechanisms that could also disable NK cell function have been described. Therefore, considering lessons learned from CAR-T cell therapy, the emergence of CAR-NK cell therapy resistance can also be envisioned. In this review we highlight the processes that could be involved in its development, focusing on cytokine addiction and potential fratricide during manufacturing, poor tumor trafficking, exhaustion within the tumor microenvironment (TME), and NK cell short in vivo persistence on account of the limited expansion, replicative senescence, and rejection by patient’s immune system after lymphodepletion recovery. Finally, we outline new actively explored alternatives to overcome these resistance mechanisms, with a special emphasis on CRISPR/Cas9 mediated genetic engineering approaches, a promising platform to optimize CAR-NK cell function to eradicate refractory cancers.

show abstract

“…Tarannum et al provides an excellent review of the different methods of NK cell expansion for adoptive NK immunotherapy [ 69 ]. Specifically, in APBHSCT, Nahi et al reported the feasibility of infusing post-APBHSCT in multiple myeloma patients multiple doses of ex vivo activated and expanded autologous NK cells.…”

Section: Engineering An Autograft Natural Killer Cell and Enhancing N...mentioning

confidence: 99%

Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Porrata

2022

Cells

View full text Add to dashboard Cite

The infusion of autograft immune effector cells directly impacts the clinical outcomes of patients treated with autologous peripheral blood hematopoietic stem cell transplantation, suggesting the possibility of an autologous graft-versus tumor cells. Furthermore, the early recovery of immune effector cells also affects survival post-autologous peripheral blood hematopoietic stem cell transplantation. Natural killer cells are among the immune effector cells reported to be collected, infused, and recovered early post-autologous peripheral blood hematopoietic stem cell transplantation. In this review, I attempt to give an update on the role of natural killer cells regarding improving survival outcomes on patients treated with autologous peripheral blood hematopoietic stem cell transplantation.

show abstract

Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy

Cited by 28 publications

References 132 publications

Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health

Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health

Overcoming tumor resistance mechanisms in CAR-NK cell therapy

Natural Killer Cells Are Key Host Immune Effector Cells Affecting Survival in Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About